Abstract: Objectives: To investigate the role of maintenance chemotherapy on the stage- Ⅲ ovarian carcinoma. Methods: Retrospective analysis of 47 cases of stage- Ⅲ ovarian carcinoma with clinical complete remission after the first-line chemotherapy. Among the patients, 21 were treated with the maintenance chemotherapy, while others were free of treatment until recurrence. The two groups were compared each other with respect to progression-free survival (PFS) and overall survivals (OS). Results: The median of the PFS was 110 weeks and 56 weeks, the median of the OS was 223 weeks and 157 weeks respectively, both in favor of maintenance group in the subgroup of suboptimal surgery (residual focus >2cm), P=0.004 and P=0.015 respectively. The difference between the two groups in the subgroup of optimal surgery (residual focus ≤2cm) was not significant. Conclusion: Patients of stage Ⅲ ovarian carcinoma with clinical complete remission maybe benefit from the maintenance chemotherapy, if the residual focus >2cm. To those with the residual foci less than 2cm, the maintenance chemotherapy will be valueless.